Citations

Clear

334 citation(s) found for "Jacobs, C".

American Clinical Neurophysiology Society Technical Standards for Performing Intraoperative Electrocorticography
Husain, Aatif, Tatum, William, Gavvala, Jay R. , Inati, Sarah, Jacobs, Julia, Gloss, David , Alkawadri, Rafeed , Nordli, Doug, Templer, Jessica W. , Keller, Crystal M., Nuwer, Marc, Gavvala, Jay R , Templer, Jessica W , Schuele, Stephan , Selioutski, Olga , Sinha, Saurabh R. , Nuwer, Marc R.

Mayo Clinic

Journal of Clinical Neurophysiology | December 29, 2025 | Volume: 43 | Issue: 2 | Pages: 101-109

10.1097/wnp.0000000000001233 | PMID 41461049 Get It

Purpose: These consensus guidelines by the American Clinical Neurophysiology Society (ACNS) describe best practices for performing intraoperative Electrocorticography (ioECoG) using subdural or depth electrodes for adult and pediatric population. Methods: A group of ACNS members was convened to develop technical standards for performing ioECoG. PubMed searches were performed to identify pertinent peer-reviewed literature. Sections were assigned to individual authors based on expertise. Consensus was achieved during subsequent group discussions to develop evidence-based recommendations to the extent possible. Recommendations: Communication between the neurosurgical and the neurophysiology teams is essential in verifying and documenting the location of the contacts. Most authors recommend ioECoG recordings of at least 5 and up to 30 minutes in duration to allow for sufficient observation of interictal activity. The anesthesia should be adjusted to allow continuous EEG activity and to minimize the effect on the ioECoG recording during general anesthesia or awake surgery. The surgical procedure and technical report should separate ioECoG recordings to define the irritative zone from ioECoG findings during functional mapping. The neurophysiology physician’s physical presence in the operating room is required in the definition of the services. Conclusion: These consensus guidelines by the ACNS describe best practices for performing intraoperative ECoG based on published literature and expert consensus.
Dietary Nitrate Intake and 16S rRNA ‐Inferred Nitrite‐Generating Capacity of the Subgingival Microbiome May Influence Glucose Metabolism: Results From the Oral Infections Glucose Intolerance and Insulin Re
Goh, Charlene En Hui, Molinsky, Rebecca , Roy, Sumith , Paster, B. J., Chen, Ching‐Yuan, Johnson, Stephen , Yuzefpolskaya, Melana, Colombo, P.C. , Rosenbaum, Michael, Knight, Rob , Desvarieux, Moïse, Jacobs, David R., Jacobs, David R. , Goh, Charlene Enhui , Goh, Charlene E , Paster, Bruce J , Jacobs, David R , Demmer, Ryan T , Molinsky, Rebecca L , Bohn, Bruno , Genkinger, Jeanine M. , Paster, Bruce J. , Rosenbaum, Michael , Desvarieux, Moı̈se, Papapanou, Panos N , Demmer, Ryan T.

Mayo Clinic

Journal of Clinical Periodontology | December 26, 2025 | Volume: 53 | Issue: 4 | Pages: 508-519

10.1111/jcpe.70084 | PMID 41448605 Get It

ABSTRACT Aims To investigate whether the association between the nitrite‐generating capacity of the subgingival microbiome and early cardiometabolic risk biomarkers varies by dietary nitrate intake. Materials and Methods Cross‐sectional data from 668 participants (mean age 31 ± 9 years, 73% women) were analysed. Dietary nitrate intake was calculated from food frequency questionnaires. Subgingival 16S rRNA sequencing (Illumina, MiSeq) and PICRUSt2 estimated microbial genes. The Microbiome‐Induced Nitric Oxide Enrichment Score (MINES) was calculated as a ratio of microbial gene abundances representing enhanced net capacity for NO generation. Adjusted multivariable linear models regressed cardiometabolic risk biomarkers (HbA1c, glucose, insulin, insulin resistance (HOMA‐IR), blood pressure) on nitrate intake and MINES together with a MINES × nitrate intake interaction term. Results Mean nitrate intake was 190 ± 171 mg/day. Significant interactions of MINES and nitrate intake were observed for insulin and HOMA‐IR ( p < 0.05). Among participants with a low MINES, higher nitrate intake was associated with lower HOMA‐IR (1.2 [1.1–1.4] vs. 1.5 [1.3–1.6]; p = 0.002), but levels were similar in those with high MINES ( p = 0.84). Conclusions A biomarker of higher microbial NO‐generating capacity in subgingival plaque is associated with lower insulin and insulin resistance among individuals with lower dietary nitrate intake. Future trials evaluating the cardiometabolic benefits of nitrate‐rich diets should incorporate measures of the entire oral microbiome.
Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA
Kabarriti, R., Lloyd, Shane , Jabalee, James , Gay, Laurie M. , Slater, T. F., Guzman, Kayleen, Jacobs, Corbin D. , Inocencio, Sean, Lin, Ray , Nguyen, Cammie , MacEwan, Iain, Crawford, Alexandra H., Rutenberg, Michael, Singh, Jaswinder, Ross, Jennifer, Kim-Wang, Sophia Y., Matthiesen, Chance, Neff, Kasha, Liu, Gene-Fu, Juarez, Tiffany , Neff, Kasha , Jacobs, Corbin , Rutenberg, Michael , Neff, Kasha , Juarez, Tiffany M , Lloyd, Shane L , Slater, Tyler, Liauw, Stanley L.

Mayo Clinic

Cancers | December 23, 2025 | Volume: 18 | Issue: 1 | Pages: 35

10.3390/cancers18010035 | PMID 41514548 Get It

Background/Objectives: Surveillance for anal squamous cell carcinoma (ASCC) recurrence relies on clinical examination and imaging. Post-treatment edema, fibrosis, and inflammation can result in clinically indeterminate findings (CIFs) that delay diagnosis and increase patient and system burden. Circulating tumor tissue-modified viral (TTMV)-HPV DNA offers a biologically specific, noninvasive biomarker that may clarify equivocal assessments. Methods: In this multi-center retrospective study, 233 patients with HPV-associated ASCC were evaluated, including 185 with ≥1 post-treatment TTMV-HPV DNA test. CIFs were defined as exams or imaging results not definitively positive or negative for disease, and were paired with subsequent TTMV-HPV DNA tests. Concordance was defined by prespecified follow-up windows comparing TTMV-HPV DNA results with subsequent clinical outcomes. Results: Ninety patients (39%) experienced 214 CIFs, arising from exams (46%, 98) or imaging (54%, 116). Indeterminate rates by assessment were 7% for exams, 17% for imaging, and 1.3% for TTMV-HPV DNA testing. Overall, 52 CIF/TTMV-HPV DNA pairs were eligible for analysis, and TTMV-HPV DNA resolved disease status accurately for 48/52 (92%, 95% CI: 81.5–97.9). Negative tests predicted cancer-free status for 37/41 CIFs (90%), while 100% of positive tests (11/11) were concordant with clinically confirmed recurrence. In 73% of positive cases (8/11), TTMV-HPV DNA was the first indication of recurrence (median lead-time 29 days; IQR 25–147). Conclusions: TTMV-HPV DNA testing reliably clarifies clinically indeterminate findings during ASCC surveillance, demonstrating high accuracy (92%) and earlier detection of recurrence. These data support integration into post-treatment management to reduce diagnostic uncertainty and guide timely care.
Staged Fenestrated Endovascular Aneurysm Repair Using Femoral Conduits in a Patient with Aortoiliac Occlusive Disease and Contemporary Literature Review
coffman, David, Farres, Houssam , Mahajan, Biraaj, Jacobs, Christopher, Polanía-Sandoval, Camilo , Coffman, David L , Mahajan, Biraaj M, Alsabbagh, Yaman , Erben, Young M, Polania-Sandoval, Camilo A , Jacobs, Christopher, Erben, Young

Mayo Clinic

Vascular and Endovascular Surgery | December 23, 2025 | Volume: 60 | Issue: 5 | Pages: 442-449

10.1177/15385744251409992 | PMID 41432028 Get It

Background: Patients with abdominal aortic aneurysms (AAA) often have comorbidities that make them poor candidates for open surgical repair (OSR). Endovascular aortic aneurysm repair (EVAR) circumvents the morbidity associated with OSR of AAA. Candidacy for EVAR is impacted by multiple factors, including the quality and size of vascular access vessels and involvement of visceral arteries, as seen in paravisceral abdominal aortic aneurysms (PVAAA). Additional challenges, such as obesity, can complicate vascular access during EVAR. PVAAA may be better suited for fenestrated EVAR (FEVAR) using a physician-modified endograft (PMEG). Materials and Methods: In this report, we describe the case of a 64-year-old female patient with a complex PVAAA in the setting of significant aortoiliac occlusive disease (AIOD) with intermittent claudication. We describe a successful staged FEVAR technique in which vascular access challenges were first addressed by recanalization of the iliac system with femoral conduit (FC) creation, followed by successful FEVAR using bilateral FC for deployment of the PMEG. Conclusion: Patients with PAAA have unique and complex pathology that are clinically challenging to address. It is not uncommon that these patients also have co-morbid conditions that make them less-than ideal candidates for open repair. Patients may also have other conditions such as AIOD which make EVAR complex. Staged approach with iliac recanalization and femoral conduit creation followed by FEVAR with PMEG is an effective treatment option for high-risk complex patients and can help avoid common complications such as groin infection and delay in FEVAR which may result in a catastrophic event such as interval AAA rupture.
Real-world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL/SLL from 2020 to 2024
Hampel, Paul J. , Kardel, Peter , Sheetz, Caitlin , Das, Ashis , Fu, Qianhong, Ding, Lee, Maglinte, Gregory A. , Ermann, Daniel A. , Wang, Xiaoliang , Das, Ashis, Ding, Lee, Seymour, Erlene Kuizon , Jacobs, Ryan W.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2723-2723

10.1182/blood-2025-2723 Get It

Abstract Background Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in US adults and incidence increases with age. Although the treatment (tx) landscape has evolved, it is unclear whether tx selection differs for older patients (pts), given concerns around comorbidities, toxicity, and efficacy. There is a need to better understand pt characteristics, tx patterns, and biomarker use among pts aged ≥65 yrs with CLL/SLL in the current therapeutic era. Methods A retrospective longitudinal study was conducted using the de-identified 100% Medicare Fee-for-Service (FFS) Research Identifiable Files. Included pts were diagnosed with CLL/SLL at age ≥65 and initiated first-line (1L) tx 1/1/2020-9/30/2024 (with ≥12 mo in database prior to 1L tx start). Index date was defined as date of 1L tx start, and pts were followed to death, end of Medicare enrollment, or study end, whichever occurred first. 1L tx was defined as any CLL pharmacologic tx within the first 90 days of index date. Tx utilization was summarized as the number and proportion of pts who received each tx at each line. Descriptive statistics were used to summarize demographic and social characteristics and baseline comorbidities, in all pts and by 1L tx. Proportion and timing of documented biomarker orders any time prior to index were summarized by test type (CLL fluorescence in situ hybridization [FISH], TP53 DNA sequencing and immunoglobulin heavy chain variable region [IGHV] test) and by 1L tx. Results Of the 21,008 pts included, median age was 76.4 yrs at 1L tx, with 43% of pts aged 65-74 yrs, 43% aged 75-84 and 14% aged ≥85. The majority of pts were male (58%) and White (91%). About 8% and 9% of pts had dual eligibility status and low-income subsidy, respectively. Median Charlson Comorbidity Index (CCI) was 4 (range: 1-21), with 40% of pts having CCI ≥5. Covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapies (mono) were most common at 1L tx (41%), including 10% zanubrutinib (zanu), 15% ibrutinib (ibr), and 16% acalabrutinib (acala). B-cell lymphoma 2 (BCL2)+anti-CD20 monoclonal antibody (mAb) was less common (11%), and chemoimmunotherapy (CIT) was used by 13% of pts, mostly BR (8%) and FCR (3%). Other less common tx included cBTKi+anti-CD20mAb (6%) or cBTKi+BCL2 therapies (1%). Among remaining pts, most received anti-CD20mAb (22%). The use of cBTKi mono increased from 41.7% in 2020 (ibr 30.6%; acala 11.1%) to 47.6% in 2024, driven by increased use of zanu (27.8%; acala 15.7%; ibr 4.2%). BCL2+anti-CD20mAb increased from 9.2% in 2020 to 12.6% in 2024. Pts treated with cBTKi mono were older than those with BCL2+anti-CD20mAb (median age 77.2 vs 74.5), and more likely to have dual eligibility status (10% vs 4%) or low-income subsidy (11% vs 5%). More pts who received zanu mono had CCI ≥5 (39%) versus acala (36%), ibr (35%), or BCL2+anti-CD20mAb (32%). Pts with BCL2+anti-CD20mAb were less likely to have diabetes (23% vs 26%), congestive heart failure (CHF; 16% vs 19%), chronic pulmonary disease (23% vs 27%), and renal diseases (23% vs 27%). Pts with ibr were less likely to have myocardial infarction (29% vs 34%), coronary artery disease (22% vs 25%), CHF (16% vs 19%), and atrial fibrillation (12% vs 18%). Overall, 69% of pts had FISH testing prior to 1L tx, but test orders for TP53 (12%) or IGHV (28%) status were infrequent. Pts with ibr had the lowest rates of TP53 tests (6%), whereas pts with CIT had the lowest rates of IGHV tests (16%). The timing of tests showed a binomial distribution where most pts received FISH, TP53, or IGHV tests either ≤60 days prior to 1L tx (46%, 50%, 33%), or &gt;1 yr before 1L tx (30%, 22%, 43%). Among pts who received ≥2 lines of therapy for CLL (n=4428; 21%), cBTKi mono was the most common in 2L (41%), including 14% zanu, 17% acala, and 10% ibr. CIT and BCL2+anti-CD20mAb were used in 12% and 9% of pts, respectively. Only 634 (3%) pts had 3L+ tx, of whom 33% received cBTKi mono, including 16% zanu, 12% acala, and 5% ibr (5%). Conclusion This large real-world study found that cBTKi mono was the most common 1L tx choice among pts aged ≥65 with CLL/SLL, with increased use of next-generation cBTKi. Pts with more baseline comorbidities were less likely to receive ibr or BCL2-based tx. FISH testing was not performed in nearly one-third of pts, and most pts did not have TP53 or IGVH sequencing prior to tx. Future studies are needed to continue to evaluate evolving tx paradigms in older pts with CLL/SLL.
Abstract 4366487: Artificial Intelligence-Enabled Electrocardiogram for the Detection of Elevated Filling Pressure in Hypertrophic Cardiomyopathy and Cardiac Amyloidosis
Lerberghe, Robin Van, Servaes, Veerle, Robyns, Tomas , Aelst, Lucas Van , Mangold, Kathryn, Oh, Jae K. , Grogan, Martha, Friedman, Paul A. , Herrmann, Joerg, Janssens, Stefan , Robyns, Tomas , Van Aelst, Lucas N L , Vandenberk, Bert , Jacobs, Johanna, Attia, Zachi I. , Oh, Jae K. , Grogan, Martha , Herrmann, Joerg

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4366487 Get It

Introduction: Diastolic dysfunction is a hallmark of heart failure with preserved ejection fraction, yet echocardiographic grading is challenging in patients with hypertrophic or amyloid cardiomyopathies due to variable structural and functional remodeling. Consequently, there is a need for additional diagnostic tools to identify patients at increased risk of diastolic dysfunction and enhanced filling pressure. Research Question: What is the accuracy of an artificial intelligence (AI)-enabled electrocardiogram (ECG) model to predict diastolic dysfunction in hypertrophic and amyloid cardiomyopathy? Methods: We included patients with diverse phenotypes of hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis and validated Mayo Clinic's AI-enabled ECG model to grade diastolic function (normal: grade 0/1; abnormal: grade 2/3). Echocardiographic analysis of systolic (LVEF) and diastolic function was performed within 14 days of ECG recording. Diastolic function was graded based on E/e’ (>14), left atrial volume index (>34 mL/m2), pulmonary venous atrial reversal flow duration (≥30 ms), and peak tricuspid regurgitation velocity (>2.8 m/s). Filling pressure was considered increased if ≥3 parameters were abnormal, inconclusive if 2 were abnomal, and normal if ≥3 were normal. Echocardiograms with severe mitral regurgitation were excluded. Results: We identified and matched 840 ECGs from non-obstructive HCM patients (n=125, age 58±19y, 70% male), 145 ECGs from obstructive HCM patients (n=29, age 56±18y, 66% male), 225 ECGs from apical HCM patients (n=33, age 66±14y, 61% male), and 382 ECGs from cardiac amyloidosis patients (n=49, age 70±13y, 57% male). The AI-enabled ECG model predicted diastolic dysfunction with an accuracy of 65% (non-obstructive HCM), 67% (obstructive HCM), 65% (apical HCM), and 75% (cardiac amyloidosis), with sensitivities of 94% and 97% for obstructive HCM and cardiac amyloidosis, respectively, and high positive and negative predictive values for cardiac amyloidosis. Systolic dysfunction (LVEF≤40%) was more common in cardiac amyloidosis (29%) than in all HCM patients (5%). Conclusion: The AI-enabled ECG model demonstrates moderate accuracy but high sensitivity for detecting diastolic dysfunction and increased filling pressure, especially in obstructive HCM and cardiac amyloidosis. The AI-enabled ECG is a useful, widely scalable, and low cost tool to identify patients at increased risk for diastolic dysfunction.
Higher Risk for Morbidity and Non-Aortic Related Mortality in Type 2 Endoleak Patients Treated Outside of Instructions for Use
Esquetini-Vernon, Camila , Farres, Houssam , Polanía-Sandoval, Camilo , Claudio-Medina, Yetzali , Morales-Arroyo, Hennessy, Ritchie, Charles , Jacobs, Christopher S., Paz‐Fumagalli, Ricardo , Toskich, Beau B. , Vandenberg, Jonathan , Mahajan, Biraaj, Jacobs, Christopher, Polania-Sandoval, Camilo A , Esquetini-Vernon, Camila , Jacobs, Christopher, Erben, Young

Mayo Clinic

Vascular and Endovascular Surgery | October 31, 2025 | Volume: 60 | Issue: 4 | Pages: 297-308

10.1177/15385744251395118 | PMID 41172539 Get It

Objective To evaluate outcomes in patients with type 2 endoleak (T2E) and the impact of treatment outside the device instructions for use (IFU). Methods This retrospective single-center study included abdominal aortic aneurysms (AAA) patients who underwent EVAR (2011- 2024). Primary outcomes were 30-day and mid-term complications, reintervention, and mortality by T2E status. Propensity score matching was applied and secondary analysis stratified outcomes by IFU compliance, comparing within ( in IFU) or outside( out IFU) IFU in each T2E group. Results Among 154 EVAR patients (137 men (89.1%) and 17 women (11.0%); mean age 77.5 ± 7.6 years), 77 were T2E(−), and 77 were T2E(+). Baseline characteristics were similar. Thirty-day complications were comparable (T2E(−): 5, 6.4% vs T2E(+): 2, 2.56%, P = 0.72). The mean follow-up duration was 2.7 ± 2.4 years. Sac diameter change (Δ) decreased in the T2E(−) (7.7 ± 8.4 mm) and enlarged in the T2E(+) (1.79 ± 12.5 mm; P < 0.01). Mid-term graft-related complications (T2E(−): 3, 3.8% vs T2E(+): 49, 62.8%, P < 0.01) and reinterventions (T2E(−): 3, 3.8%, vs T2E(+): 20, 25.6% P < 0.01) were higher in the T2E(+) with no difference in mortality ( P = 1.00). These findings remained after excluding type 1 endoleaks. Among the T2E(+), those treated out IFU had longer hospital stays ( out IFU: 3.0 ± 2.8 days vs in IFU: 1.8 ± 2.0 days, P = 0.03), higher T1E ( out IFU: 3, 33.3% vs in IFU: 1, 4.34%, P < 0.01), higher rates of reintervention ( out IFU: 9, 100.0% vs in IFU:17; 24.6%, P < 0.01) and higher all-cause mortality than those within IFU criteria ( out IFU: 5, 55.0% vs in IFU: 13, 18.8%, P < 0.01). IFU status did not significantly affect outcomes in T2E(−) patients. Conclusions T2E is associated with sac growth and increased reinterventions, but not higher mortality. On subgroup analysis, those T2E(+) treated out IFU had longer hospitalizations, higher T1E rates, more reinterventions, and higher all-cause; but not aneurysmal-related mortality.
Immigration Enforcement Tactics and Systemic Health Harms: The Ethical Imperative for Medical Advocacy
Jacobs, Jeremy W. , Bibb, Lorin A. , Gutierrez, Juan Raul , Allan, Jessica M. , Horstman, Erin , Landry, Adaira , Martin, Amarilis , Shelton, K. Maureen, Wheeler, Allison P. , Landry, Adaira I , Shelton, Kathryn Maureen, Jacobs, Jeremy W , Wheeler, Allison P

Mayo Clinic

Annals of Internal Medicine | October 27, 2025 | Volume: 178 | Issue: 12 | Pages: 1793-1795

10.7326/annals-25-03151 | PMID 41144968 Get It

Robotic-Assisted Vascular Surgery: Current Landscape, Challenges, and Future Directions
Alsabbagh, Yaman , Jlilati, Adeeb , Sarmiento, Joaquin, Jacobs, Christopher R. , Elli, Enrique F. , Farres, Houssam , Jlilati, Adeeb , Jacobs, Christopher, Farres, Houssam , Erben, Young , Jacobs, Christopher

Mayo Clinic

Journal of Clinical Medicine | October 17, 2025 | Volume: 14 | Issue: 20 | Pages: 7353

10.3390/jcm14207353 | PMID 41156226 Get It

Vascular surgery has evolved from durable yet invasive open reconstructions to less traumatic endovascular techniques. While endovascular repair reduces perioperative morbidity, it introduces durability challenges and the need for lifelong surveillance. Laparoscopic surgery bridged some gaps but was hindered by steep learning curves and technical limitations. Robotic-assisted surgery represents a “third revolution”, combining the durability of open repair with the recovery and ergonomic benefits of minimally invasive approaches through enhanced 3D visualization, wristed instrumentation, and tremor filtration. This review synthesizes current evidence on robotic applications in vascular surgery, including aortic, visceral, venous, and endovascular interventions. Feasibility of robotic vascular surgery has been demonstrated in over 1500 patients across aortic, visceral, venous, and decompression procedures. Reported outcomes include pooled conversion rates of ~5%, 30-day mortality of 1–3%, and long-term patency rates exceeding 90% in aortoiliac occlusive disease. Similarly favorable outcomes have been observed in AAA repair, visceral artery aneurysm repair, IVC reconstructions, renal vein transpositions, and minimally invasive decompression procedures such as median arcuate ligament and thoracic outlet syndromes. Endovascular robotics enhances catheter navigation precision and reduces operator radiation exposure by 85–95%, with multiple series demonstrating consistent benefit compared to manual techniques. Despite these advantages, adoption is limited by high costs, lack of dedicated vascular instruments, absent haptic feedback on most platforms, and the need for standardized training. Most available evidence is observational and from high-volume centers, highlighting the need for multicenter randomized trials. Future directions include AI-enabled planning and augmented-reality navigation, which are the most feasible near-term technologies since they rely largely on software integration with existing systems. Other advances such as microsurgical robotics, soft-robotic platforms, and telesurgery remain longer-term developments requiring new hardware and regulatory pathways. Overcoming barriers through collaborative innovation, structured training, and robust evidence generation is essential for robotics to become a new standard in vascular care.
Accelerating eSource scale-up in oncology clinical trials: The i~HD Task Force initiative
Kalra, Dipak, Acito, Tracy, Ammour, Nadir, Basset, Paul, Castleyn, Peter, Caldow, Ross, Couvert, Camille, Cramer, Amy, Harrison, Chris, Holtzem, Joeri, Mariappan, P., Jacobs, Paul, Fransson, Lars, Berthou, Véronique, Jackson, Laurice, Wetzel, Nancy, Thompson, C. C. , Klein, Sharon , Kaoukdji, Fakhry, Ward, Michael, Lengfellner, Joe, Patruno, Anna, Snow, Dawn, Virchow, Isabel , Fritsche, Angela, Coorevits, Pascal , Sundgren, Mats , Sundgren, Mats , Maes, Christophe, Kalra, Dipak, Ammour, Nadir, Burge, Sarah , Caldow, Ross, Couvert, Camille, Cramer, Amy, Mariappan, Pavitra, Jacobs, Paul, Wetzel, Nancy, Thompson, Christopher, Klein, Sharon, Green, Robert, Kaoukdji, Fakhry, Ward, Michael, Nensa, Felix , Lengfellner, Joe, Patruno, Anna, Snow, Dawn, Fritsche, Angela

Mayo Clinic

Cambridge Prisms: Precision Medicine | October 14, 2025 | Volume: 3 | Issue: No issue available | Pages: No page available

10.1017/pcm.2025.10004 | PMID 41306345 Get It

Abstract eSource – particularly EHR-to-EDC – is an emerging paradigm in clinical research that enables automated transfer of electronic health record (EHR) data into electronic data capture (EDC) systems, with the potential to reduce site burden, improve data quality and accelerate oncology clinical trial workflows. However, widespread implementation remains limited due to technical, regulatory and operational barriers. To address these challenges, the European Institute for Innovation through Health Data (i~HD) launched the eSource Scale-Up Task Force in 2024. This multi-stakeholder initiative brings together leading oncology centres and pharmaceutical sponsors to establish a consensus-driven roadmap for eSource adoption. Central to this effort are three foundational resources: readiness criteria for early adopters, a performance indicator framework for monitoring success and an operational playbook to guide implementation. This article provides a structured overview of the Task Force’s objectives, collaborative model and outputs, with specific attention to its focus on interoperability, regulatory alignment and real-world validation. While initially developed for oncology, the Task Force’s framework is applicable across therapeutic areas characterized by data-intensive workflows.